On The Low-Frequency Vibrational Modes of C60_{60}

The vibrational spectrum of C$_{60}$ is compared to the spectrum of a classical isotropic elastic spherical shell. We show correlations between the low frequency modes of C$_{60}$ and those of the spherical shell. We find the spherical model gives the approximate frequency ordering for the low frequency modes. We estimate a Poisson ratio of $\sigma\approx 0.30$ and a transverse speed of sound of $v_s\approx 1800$ m/s for the equivalent elastic shell. We also find that $\omega({\rm M_1})/\omega({\rm M_0})=\sqrt{3\over 2}$ for the shell modes ${\rm M_0}$ and ${\rm M_1}$, independent of elastic constants. We find that this ratio compares favorably with an experimental value of 1.17.Comment: 11 pages, 3 figures in Postscript, uses REVTEX, to be published in Chem. Phys. Let

The Biosimilars Act: The United States’ Entry into Regulating Biosimilars and its Implications, 12 J. Marshall Rev. Intell. Prop. L. 322 (2013)

The Patient Protection and Affordable Care Act is most well-known for creating a mandate requiring individuals to have health insurance. However, another provision of the Act, the Biologics Price Competition and Innovation Act, created a new process for companies to introduce biosimilars, products that are highly similar to licensed drugs in terms of purity, safety, and potency, but have minor differences in the inactive ingredients. This provision seeks to alleviate strain on companies introducing biosimilars by creating an abbreviated pathway for their approval by the Food and Drug Administration, similar to an Abbreviated New Drug Application under the Hatch-Waxman Act. This article provides a comprehensive overview of the Biologics Price Competition and Innovation Act and contrasts it with the Hatch-Waxman Act and European Law on Biosimilars. Strategies for patent claiming and resolving patent disputes are then discussed

Recent Decisions

Comments on recent decisions by Robert P. Gorman, Edward J. Griffin, John E. Roberts, Ralph R. Blume, Raymond P. Knoll, Manuel A. Sequeira, Jr., James E. Sullivan, Edward S. Mraz, Paul M. Kraus, J. Robert Geiman, John F. Chmiel, and Jack Economou

Description of regional mitral annular nonplanarity in healthy human subjects: A novel methodology

ObjectiveFinite-element analysis demonstrates that the nonplanar shape of the mitral annulus diminishes mitral leaflet stress. It has therefore been postulated that repair with annuloplasty rings that maintain the nonplanar shape of the annulus could increase repair durability. Although the global nonplanarity of the mitral annulus has been adequately characterized, design of such a ring requires a quantitative description of regional annular geometry. By using real-time 3-dimensional echocardiography in conjunction with available image processing software, we developed a methodology for describing regional annular geometry and applied it to the characterization of the normal human mitral annulus.MethodsFive healthy volunteers underwent mitral valve imaging with real-time 3-dimensional echocardiography. Regional annular height was calculated at 36 evenly spaced intervals.ResultsMaximal annular height/commissural width ratio was found to occur at the midpoint of the anterior annulus in all cases. These values averaged 26% ± 3.1%, whereas those for the midposterior annulus averaged 18% ± 3.0%. The average commissural width was 35.2 ± 6.0 mm. Although substantial spatial heterogeneity was observed, regional annular height at a given rotational position was highly conserved among subjects when normalized to commissural width.ConclusionsThese quantitative imaging and analytic techniques demonstrate that the normal human mitral annulus is regionally heterogeneous in its nonplanarity, and they establish a means of describing annular geometry at a regional level. With wider application, these techniques may be used both to characterize pathologic annular geometry and to optimize the design of mitral valve annuloplasty devices

The Otterbein Miscellany - Spring 1991

https://digitalcommons.otterbein.edu/miscellany/1003/thumbnail.jp

PROTOCOL: New York State Race, Ethnicity, and Insurance Disparities in Follow-up Prostate Cancer Screening

Using de-identified reports from the Statewide Planning and Research Cooperative System (SPARCS) data, this descriptive study will identify the impact of socioeconomic status (SES) metrics on the follow-up prostate cancer screening care within 3 years of index prostate cancer screening test in NYS. The socioeconomic status metrics will be subclassified into race, insurance, and ethnicity and each of these sub-components will be evaluated for its impact on the follow-up cancer screening care. The exclusion criteria for this study includes patients records with unknown age, age \u3c55 or \u3e75, previous history of prostate cancer or radical prostatectomy, previous prostate biopsy, female sex, lives outside NYS, unknown or missing data on race, ethnicity, or insurance status, or multi-ethnic patients. For the included patients, initial prostate cancer screening, follow-up screening, characteristics (e.g., age, SES), and risk profiles will be evaluated. Moreover, patients diagnosed with prostate cancer or receiving prostatectomy will be reported. Additionally, the following hypotheses will be tested: H(0): Among patients with a baseline PSA test, socioeconomic status (SES) metrics (i.e., vulnerability based upon race/insurance/ethnicity) may pose as barriers to follow-up prostate cancer screening care within 3 years of index prostate cancer screening test (e.g., Vulnerability = V = Black, Hispanic, and Self-pay Insurance) o H(0): Among patients with a baseline PSA test, race does not impact the likelihood of follow-up prostate cancer screening care within 3 years of index prostate cancer screening test (e.g., R-FC) o H(0): Among patients with a baseline PSA test, insurance does not impact the likelihood of follow-up prostate cancer screening care within 3 years of index prostate cancer screening test (e.g., I-FC) o H(0): Among patients with a baseline PSA test, ethnicity does not impact the likelihood of follow-up prostate cancer screening care within 3 years of index prostate cancer screening test (e.g., E-FC

Photochemically controlled drug dosing from a polymeric scaffold

Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-3,5-dimethoxybenzoin (DMB) conjugates in a poly(2-methyoxyethyl acrylate) (pMEA) scaffold. Methods Flurbiprofen- and naproxen-DMB conjugates were prepared via esterification and characterised via NMR spectroscopy and mass spectrometry following chromatographic purification. Conjugate photolysis was investigated in acetonitrile solution and within the pMEA matrix following exposure to low-power 365 nm irradiation. Photo-liberation of drug from pMEA into phosphate buffered saline was monitored using UV-vis spectroscopy. Results The synthetic procedures yielded the desired drug conjugates with full supporting characterisation. Drug regeneration through photolysis of the synthesised conjugates was successful in both acetonitrile solution and within the pMEA scaffold upon UV irradiation. Conjugates were retained within the pMEA scaffold with exclusive drug liberation following irradiation and increased drug dose with increasing exposure. Multi-dosing capacity was demonstrated though the ability of successive irradiation periods to generate further bursts of drug. Conclusion This study demonstrates the first application of photochemically controlled drug release from a biomaterial coating and the feasibility of using pMEA as a scaffold for housing the photoactive drug-DMB conjugates